Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic

Authors	SKŘIČKOVÁ Jana CHLOUPKOVÁ Renata HEJDUK Karel PEŠEK Miloš KOLEK Vítězslav KOUBKOVÁ Leona ROUBEC Jaromír ČERNOVSKÁ Markéta SALAJKA František KREJČÍ Jana HAVEL Libor TOMÍŠKOVÁ Marcela ŠATÁNKOVÁ Monika BENEJOVÁ Andrea GRYGÁRKOVÁ Ivona HRNČIARIK Michal ZEMANOVÁ Milada SIXTOVÁ Dimka MERTA Zdeněk
Year of publication	2017
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05).